Showing results (21-30 of 140) with videos related to
Sort By:
Pageof 14
Expert Opinion on Investigational Drugs|May 30, 2014
Afatinib in the treatment of breast cancerSara A Hurvitz, Rebecca Shatsky, Nadia HarbeckDrugs|June 30, 2019
Advances in Targeted Therapies for Triple-Negative Breast CancerKelly E McCann, Sara A Hurvitz, Nicholas McAndrewTherapeutic Advances in Medical Oncology|March 17, 2022
Oncotype DX Recurrence Score in premenopausal womenShiliang Zhang, Kasey C Fitzsimmons, Sara A HurvitzDrugs in Context|February 20, 2018
Harnessing the immune system in the battle against breast cancerElizabeth S Nakasone, Sara A Hurvitz, Kelly E McCannAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Optimal Management of Early and Advanced HER2 Breast CancerSara A Hurvitz, Karen A Gelmon, Sara M TolaneyCancer Treatment Reviews|September 10, 2013
Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancerParvin F Peddi, Rebecca A Shatsky, Sara A HurvitzCancer Treatment Reviews|June 5, 2012
Current approaches and future directions in the treatment of HER2-positive breast cancerSara A Hurvitz, Yufang Hu, Neil O'Brien, et al.Breast Cancer Research and Treatment|November 13, 2013
Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancerSara A Hurvitz, Deepa Lalla, Ross D Crosby, et al.Breast Cancer Research and Treatment|September 17, 2021
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancerHannah Van Belle, Sara A Hurvitz, Peter J Gilbar, et al.Therapeutic Advances in Medical Oncology|April 11, 2022
Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysisSanaz N Ghafouri, Rebecca W Nayeri, Nicholas P McAndrew, et al.Pageof 14